

SCHEMA

For patients with oropharyngeal cancer (OPC) or cancer of unknown primary (CUP):
Local p16 determination by immunohistochemistry is required.

For patients with laryngeal and hypopharyngeal primaries:
Analysis of p16 status is **not required**.

STRATIFY

- Zubrod (ECOG) performance status: 0 vs. 1
- Smoking status: ≤ 10 pack-year vs. > 10 pack-year history
 - T stage: T0-3 vs. T4
 - Age: ≤ 50 vs. > 50 years

RANDOMIZE (1:1 in each cohort)

Non-OPC/p16-negative OPC Cohort

Arm 1: IMRT/IMPT + High-dose cisplatin
Q 3 weeks

Arm 2: IMRT/IMPT + Low-dose cisplatin
weekly

p16-positive OPC/CUP Cohort

Arm 3: IMRT/IMPT + High-dose cisplatin
Q 3 weeks

Arm 4: IMRT/IMPT + Low-dose cisplatin
weekly